Influence of recurrent vulvovaginal candidiasis on quality of life issues
Carregando...
Citações na Scopus
30
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Citação
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, v.300, n.3, p.647-650, 2019
Resumo
Purpose More than 370 million women will experience recurrent vulvovaginal candidiasis (RVVC) during their lifetime. However, RVVC is often trivialized as clinically insignificant and not worthy of research funding. We evaluated the influence of RVVC on the quality of life in affected women. Methods The validated World Health Organization Quality of Life Abbreviated Assessment (WHOQOL-Bref) questionnaire was administered to 100 women with RVVC and to 101 epidemiologically matched women with no history of vulvovaginal candidiasis. RVVC was defined as at least four episodes of clinical and culture-positive vaginal candidiasis within a 1 year period. Data were analyzed by Chi square, Student t test and analysis of variance. Internal consistency of responses to questions was evaluated by Cronbach alpha. Results The Cronbach alpha coefficient was > 0.80 for responses to generalized questions and > 0.65 for answers to more specific questions, indicating substantial internal consistency. Perception of quality of life and satisfaction with their health was greatly reduced in the RVVC group (p < 0.001). Diminished responses to physical and psychological well-being were also reported by women with RVVC (p < 0.001). Various aspects of social relations including sexual activity were similarly reduced (p < 0.001) as were satisfaction with issues such as home environment, financial resources and employment (p < 0.001). Conclusion RVVC affects multiple aspects of a woman's well-being. Women with this condition deserve serious attention from clinicians and research into susceptibility, prevention and treatment of this infection deserves much greater emphasis.
Palavras-chave
Health questionnaire, Quality of life, Recurrent vulvovaginal candidiasis
Referências
- Aballea S, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-169
- Babula O, 2003, CLIN INFECT DIS, V37, P733, DOI 10.1086/377234
- Cassone A, 2015, BJOG-INT J OBSTET GY, V122, P785, DOI 10.1111/1471-0528.12994
- Chapple A, 2001, HEALTH EDUC RES, V16, P9, DOI 10.1093/her/16.1.9
- Denning DW, 2018, LANCET INFECT DIS, V18, pE339, DOI [10.1016/s1473-3099(18)30103-8, 10.1016/S1473-3099(18)30103-8]
- Giraldo P, 2000, OBSTET GYNECOL, V95, P413, DOI 10.1016/S0029-7844(99)00577-3
- Goncalves B, 2016, CRIT REV MICROBIOL, V42, P905, DOI 10.3109/1040841X.2015.1091805
- Ilkit M, 2011, CRIT REV MICROBIOL, V37, P250, DOI 10.3109/1040841X.2011.576332
- Linhares L M, 2001, Infect Dis Obstet Gynecol, V9, P221
- Nguyen Y, 2017, AUSTRALAS J DERMATOL, V58, pE176, DOI 10.1111/ajd.12487
- Sobel JD, 2016, AM J OBSTET GYNECOL, V214, P15, DOI 10.1016/j.ajog.2015.06.067
- Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114
- Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd
- WITKIN SS, 1988, J ALLERGY CLIN IMMUN, V81, P412, DOI 10.1016/0091-6749(88)90909-8
- World Health Organization Division of Mental Health, 1996, WHOQOL BREF INTR ADM
- Zhu YX, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0470-2